Table 3.
Envelope genotype | Reciprocal serum neutralizing antibody titer |
|||
---|---|---|---|---|
90% |
50% |
|||
1a (H06) | 4a (AA) | 1a (H06) | 4a (AA) | |
1a | 50 | <50 | 1,600 | 50 |
2a | <50 | <50 | <50 | <50 |
3a | <50 | <50 | <50 | <50 |
4a | 800 | 400 | 12,800 | 6,400 |
5a | 3,200 | 800 | 25,600 | 3,200 |
6a | 25,600 | 3,200 | 204,800 | 25,600 |
Approximately 100 TCID50 of JFH1-based recombinant virus containing Core-NS2 of each of the six major genotypes was incubated in triplicates with a 2-fold dilution series of genotype 1a or 4a chronic-phase patient serum or a mixture of sera from four HCV negative controls and tested in Huh7.5 cells. Reciprocal neutralization titers are indicated as the highest dilution showing a reduction in FFUs of at least 90% or 50% compared to HCV-negative controls.